GLAXO Stock Overview
Manufactures, distributes, and trades in pharmaceuticals in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
GlaxoSmithKline Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,508.70 |
| 52 Week High | ₹3,088.00 |
| 52 Week Low | ₹1,842.05 |
| Beta | 0.24 |
| 1 Month Change | 19.02% |
| 3 Month Change | 4.02% |
| 1 Year Change | 15.57% |
| 3 Year Change | 65.35% |
| 5 Year Change | 92.09% |
| Change since IPO | 1,009.68% |
Recent News & Updates
GlaxoSmithKline Pharmaceuticals Limited Just Recorded A 8.7% Revenue Beat: Here's What Analysts Think
Feb 19
Subdued Growth No Barrier To GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Price
Jan 22Recent updates
GlaxoSmithKline Pharmaceuticals Limited Just Recorded A 8.7% Revenue Beat: Here's What Analysts Think
Feb 19Subdued Growth No Barrier To GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Price
Jan 22GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Nov 01We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%
Jun 01With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case
May 05GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear
Apr 14Shareholder Returns
| GLAXO | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 24.3% | -0.6% | 0.3% |
| 1Y | 15.6% | 7.4% | -1.4% |
Return vs Industry: GLAXO exceeded the Indian Pharmaceuticals industry which returned 9.4% over the past year.
Return vs Market: GLAXO exceeded the Indian Market which returned -0.6% over the past year.
Price Volatility
| GLAXO volatility | |
|---|---|
| GLAXO Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: GLAXO has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: GLAXO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1924 | 3,211 | Bhushan Akshikar | india-pharma.gsk.com |
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease.
GlaxoSmithKline Pharmaceuticals Limited Fundamentals Summary
| GLAXO fundamental statistics | |
|---|---|
| Market cap | ₹425.01b |
| Earnings (TTM) | ₹8.59b |
| Revenue (TTM) | ₹37.05b |
49.5x
P/E Ratio11.5x
P/S RatioIs GLAXO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLAXO income statement (TTM) | |
|---|---|
| Revenue | ₹37.05b |
| Cost of Revenue | ₹14.27b |
| Gross Profit | ₹22.78b |
| Other Expenses | ₹14.19b |
| Earnings | ₹8.59b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Aug 01, 2025
| Earnings per share (EPS) | 50.72 |
| Gross Margin | 61.49% |
| Net Profit Margin | 23.19% |
| Debt/Equity Ratio | 0.9% |
How did GLAXO perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yield92%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 05:05 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GlaxoSmithKline Pharmaceuticals Limited is covered by 25 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shirish Pardeshi | Anand Rathi Shares and Stock Brokers Limited |
| Sarabjit Nangra | Angel Broking Private Limited |
| Prakash Agarwal | Axis Capital Limited |